U.K. and Germany take different steps on drug spending

The U.K. government has adopted policies viewed as more favorable to pharmaceutical companies and pledged higher medicine spending after campaigns from industry groups and the Trump administration. Germany has proposed measures to reduce health budget deficits by cutting spending and raising industry fees.

Policy directions in two markets The moves come as European countries consider how to address drug prices, with effects on both companies and patients. The U.K. approach includes commitments to increase spending on medicines. Germany's proposals focus on lowering outlays and increasing payments required from the industry.

U.S. role in European pricing debates The developments occur as the U.S. observes European pricing decisions. The two largest economies on the continent are pursuing opposite directions on pharmaceutical spending.